Mr. Stewart: Amarin is a specialty pharmaceutical company which licenses and markets drugs to treat very specific neurological diseases in the U.S. Amarin has its headquarters in London, with US sales and marketing offices in San Francisco, and research and development in Malmo, Sweden. We currently employ over 100 people worldwide and are traded on the Nasdaq (AMRN). Amarin’s objective is to become a leader & best in class n neurology. We have already established a strong reputation in this area and intend to strengthen this through an incremental strategy of disease management in Parkinson's, Huntington's and other movement disorders including ALS (Lou Gehrig’s disease). It is a very simple strategy. In Parkinson's disease there are currently four primary treatments: carbidopa levodopa; dopamine agonists; MAO-B inhibitors; and COM-Ts. Apart from Novartis, Amarin is the only other company in the US which has got two out of the four treatments. Our objective is to obtain the other two treatments either via acquisition or co-promotion so that our sales force effectively becomes a consultant to the neurologists. Effectively, our sales force can discuss with the neurologist where the patient is in their disease progression and can offer a full product line for treatment. No other pharmaceutical company can do this Amarin has adopted a low-risk approach to building its neurology franchise. The way we intend to execute going forward is to combine in-market product acquisitions with establishing a late stage development pipeline. Historically, we have been quite successful at that. Permax®, our dopamine agonist, which went generic at the beginning of the year was instrumental in growing revenues and establishing our US sales and marketing infrastructure. Our late stage development pipeline consists of Zelapar®, our new MAO-B inhibitor, which is currently with the FDA. We have received an approvable letter for Zelapar® and we are in discussions with the FDA at the moment. LAX-101 is our other late stage development product, it is the only potential treatment for Huntington's disease. We have conducted an initial Phase III study and we will be conducting further Phase III studies next year. So it is quite a simple but unusual strategy in so far as we are absolutely dedicated to the field of neurology. There is no other company that is doing this at the present time.
Tickers included in this excerpt: AMRN
For more information call (212) 952 7433. The Wall Street Transcript does not endorse any of the comments made by interviewees, and does not make stock recommendations.